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Abstract 
Background & Purpose: Opioid maintenance therapy (OMT) is an effective method of treating 
opioid addiction. Of incarcerated individuals in the U.S., 50-85% have a history of substance 
abuse, and >80% of inmates with opioid addiction history do not receive treatment. The purpose 
of this study was to explore individuals’ experiences after being tapered from OMT upon 
incarceration. Methods: Interpretative phenomenological analysis (IPA) was employed using in-
depth interviewing of 10 participants. Results: Analysis identified six themes that captured the 
essence of the participants’ experiences. Implications & Conclusion: Losing OMT upon 
incarceration was described as an extremely stressful experience for many individuals, and may 
create issues for both inmates and facility staff. Further research is needed to discover ways in 
which to improve addiction treatment in prison. 
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Substance related offenses are responsible for at least half of federal prison sentences. 
Between 50-85% of incarcerated individuals in the U.S. have a history of substance abuse, with 
20% of those reporting intravenous (IV) drug use (Nunn 2009).  Between 9-13% of incarcerated 
individuals in 2004 reported using heroin on a regular basis pre-incarceration (Mumola & 
Karberg, 2006), and between 12%-25% of newly arrested individuals tested positive for opioids 
upon urinalysis (National Institute of Justice, 2004). The availability of illicit substances in 
prisons has been well documented (United Nations Office on Drugs and Crime, 2010), and 
needle-sharing behaviors in prison settings greatly increase risk for HIV and hepatitis C 
acquisition during incarceration (United Nations Office on Drugs and Crime, 2010). Opioid 
maintenance treatment (OMT) with either methadone or buprenorphine is an effective method of 
decreasing opioid abuse and promoting increased health in community and prison settings. It has 
also been found to decrease individual involvement with the criminal justice system and 
HIV/hepatitis C infection (Gordon, Kinlock, Schwartz, O’Grady, 2008) as well as increase 
quality of life in the community-dwelling population (Nosyk et al., 2012). While detoxification 
programs are also utilized for treatment of opioid dependence, they have been found to be less 
effective than OMT at reducing illicit behaviors, substance use, and needle sharing (Nosyk et al., 
2012).  The World Health Organization has called for OMT to play a major role in substance 
abuse programs, including those in prison settings (2013), and the National Institute on Drug 
Abuse (NIDA) includes OMT in its principle for addiction treatment of both the general and 
inmate population (2012). 
Opioid maintenance treatment in the prison setting has been found to result in a decrease 
in opioid use as well as decreased drug injecting and needle sharing (NIDA, 2012). While 
inmates frequently report accessibility to illicit substances and means to inject drugs in prison, 
only 55% of U.S. state and federal prisons provide methadone or buprenorphine, and more than 
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half of those prisons only do so for pregnant women or to treat chronic pain rather than addiction 
(Nunn 2009). More than 80% of inmates with known addiction histories do not receive treatment 
while incarcerated (Chandler, Fletcher & Volkow, 2009). Many incarcerated individuals with a 
history of opioid abuse have been enrolled in an OMT program prior to incarceration (Fiscella, 
Moore, Engerman, Meldrum, 2004), but rates of initiation into OMT after release from prison are 
low, and the risk of overdose is elevated in the period immediately following reintegration back 
into the community (World Health Organization, 2013).  Hendrich et al. (2011) found that six 
months following release from prison, more than 50% of individuals who were able to receive 
OMT in prison continued treatment in the community, while only five percent of individuals who 
did not receive OMT while incarcerated enrolled in a community-based OMT program upon 
release from prison. Individuals with a history of pre-incarceration heroin addiction typically 
relapse within one month of release from prison if they are not enrolled in an OMT program 
(Gordon, Kinlock, Schwartz, O’Grady, 2008). Reasons for relapse can include anxiety and 
depression related to “stigma associated with being labeled an ex-offender, the need for housing 
and legitimate employment, stresses in reunifying with family, and multiple requirements for 
criminal justice supervision,” (p. 184) as well as reintegration into a community where substances 
are highly available and accessible (Chandler, Fletcher, & Volkow, 2009). 
Rates of successful long term, voluntary tapers from OMT in medically supervised 
community-based treatment centers are generally considered poor. Nosyk et al.’s (2012) 
population-based, retrospective cohort study found that only 13% of community-dwelling 
individuals who attempted a medically supervised, voluntary taper from OMT were considered 
successful, meaning they avoided relapse and/or reentry into OMT. Calsyn, Malcy, & Saxon 
(2006) reported a zero percent success rate following a voluntary, medically supervised 
methadone taper. However, because the accessibility of OMT in prison settings is poor, many 
individuals who are enrolled in an OMT program are involuntarily tapered from methadone or 
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buprenorphine upon incarceration at a rate that is much faster than what is generally considered 
appropriate within a community-based OMT setting (Fiscella, Moore, Engerman, Meldrum, 
2004).  
Purpose 
Given the stress associated with incarceration, it is important to explore the experiences 
of individuals who have undergone involuntary discontinuation or taper while serving time in 
prison. The purpose of this study was to discover, explore, and describe these experiences. 
Implicit within the goal is to discover the essence of their experience during this time and learn 
about what the experience was like for them. 
Research Question  
The overarching research question was: “what are the experiences of individuals who are 
tapered from OMT upon incarceration?” Secondary aims explored how being tapered from OMT 
affected the participants’ lives following release and reintegration back into the community. 
Significance 
  Little is known about the experiences of individuals who were tapered from OMT when 
incarcerated. This study provided information about the experiences of individuals tapered off of 
OMT, which is lacking in the current literature. The study findings may help guide further 
research in this area, which will help inform future policies about the delivery of addiction care in 
prison settings. This is particularly important considering the percentage of incarcerated 
individuals who report past or present substance abuse and addiction. 
Advanced Practice Registered Nurse (APRN) Competencies 
  This study integrated the APRN competencies related to scientific foundations, quality of 
care, health policy, and health care delivery. The purpose of this study was to generate data about 
the experiences of individuals, the analysis of which inform health policy and improve the quality 
of nursing and healthcare for the incarcerated and drug-using populations. In these ways, this 
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study integrated all four of the previously stated competencies. A nurse researcher is the principal 
investigator and will collaborate with other nurses, medical providers, and counselors at a 
community OMT clinic to successfully complete the proposed study, thereby fulfilling the APRN 
















Comprehensive Literature Review 
 This review of the literature will begin by providing background information about 
opioid maintenance treatment. It will then examine the current research relating to the effect of 
OMT on quality of life and overdose risk of community dwelling populations. It will conclude by 
reviewing research of OMT’s use and effect in prison settings. 
Opioid Maintenance Treatment 
 
 Opioid maintenance treatment (also known as replacement or substitution therapy) refers 
to the use of either methadone or buprenorphine to treat opioid addiction. Methadone is a full 
opioid agonist and buprenorphine is a partial opioid agonist, and both medications function by 
binding to opiate receptors and reducing drug withdrawal symptoms and drug cravings (Whelan 
and Remski, 2012). Correct doses of methadone and buprenorphine (which vary between 
patients) can also inhibit the effects of other opioids so that the “high” that is desired when an 
individual uses another opioid is not achieved. The primary goals of treatment are to help 
individuals addicted to opioids refrain from using illicit substances and abusing opioid 
prescription pain medication, decrease withdrawal symptoms, and aid in addiction recovery 
(Centers for Disease Control, 2002). Treatment with methadone or buprenorphine does not come 
without risks, as either of the medications can cause dose-dependent intoxication or fatality. Both 
medications also have abuse potential and are therefore subject to diversion and street dealing.  
(Whelan and Remski, 2012). In a randomized study comparing buprenorphine (16-32mg), low 
dose methadone (20mg), and high dose methadone (60-100mg), buprenorphine and high dose 
methadone were found to be equally more effective at reducing opioid abuse than low dose 
methadone, without significant differences in reported side effects (Johnson, Chutuape, Strain, 
Walsh, Stitzer & Bigelow, 2000).  
Opioid maintenance therapy is most often administered at outpatient substance abuse 
clinics and inpatient treatment centers, and its effectiveness is increased when it is paired with 
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other treatment modalities such as counseling and group meetings such as 12-step programs 
(NIDA, 2012). Buprenorphine is a newer medication in the treatment of opioid addiction and has 
not been as widely utilized as methadone. It is administered at substance abuse treatment centers 
as well as in primary care settings by independent providers with special licensing. When utilized 
for substance abuse treatment purposes (as opposed to pain management), methadone must be 
administered through a federally certified substance abuse clinic (Substance Abuse and Mental 
Health Services Administration, 2013). The choice of medication to treat opioid addiction is 
related to numerous factors including level of opioid dependence, prescriber preference, and 
medication availability (Whelan and Remski, 2012). There are currently no clear, universal 
guidelines to help prescribing clinicians decide whether methadone or buprenorphine is 
appropriate for their patients. Some clinicians utilize their patients’ drug-use histories to 
determine if buprenorphine will be effective, as individuals with heavier illicit opioid use might 
be better maintained on methadone as it can be successfully titrated to higher doses than 
buprenorphine (V. Esparza, personal interview, April 1, 2014). Buprenorphine is also more 
expensive in the United States than is methadone, which may affect prescribing in some 
situations (V. Esparza, personal interview, April 1, 2014).  
The administration of OMT requires careful upward titration to ensure that patients 
receive a dose that eliminates withdrawal symptoms without causing intoxication, and the optimal 
dosage differs from patient to patient. Both medications also cause withdrawal symptoms when 
discontinued abruptly and slow tapering is advised to decrease the severity of withdrawal 
symptoms. Withdrawal symptoms can be extremely uncomfortable and include diarrhea, nausea, 
vomiting, body aches, sweating, chills, tremors, irritability, intense opioid cravings, and anxiety; 
these symptoms are reportedly so unbearable that stopping or even decreasing use is extremely 
difficult for most individuals to tolerate without some form of treatment (Harvard Medical 
School, 2004). Neurobiological changes in the brain from chronic drug exposure may 
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significantly limit impulse control in individuals suffering from opioid addiction, which can 
provide an extra challenge for individuals attempting to stop using substances (Chandler, 
Fletcher, Volkow, 2009). Opioid withdrawal is generally not life threatening, but it can cause 
miscarriage in pregnant individuals (Harvard Medical School, 2004).  
Quality of Life and Opioid Maintenance Therapy 
 
While there is a lack of information about the ways in which opioid maintenance 
treatment impacts the quality of life of prisoners, OMT has been found to have a positive effect 
on quality of life ratings of individuals in community settings. Baharom, Hassan, Ali and Shah 
(2012) conducted a retrospective chart review to compare quality of life for 122 men with 
histories of opioid addiction before beginning OMT to quality of life after six months of OMT at 
a Malaysian community clinic. The World Health Organization Quality of Life survey was 
administered at baseline and after six months in treatment and these scores were compared for 
changes in four categories: physical, psychological, relationships, and living 
situation/environment. The researchers found that six months of OMT was associated with 
significantly higher scores in all four categories, with the psychological category showing the 
most significant improvement.  
A qualitative study conducted by De Maeyer et al. (2011) in Belgium utilizing in-depth 
interviews uncovered five recurrent themes that were associated with quality of life for 
individuals who had been enrolled in a community-based OMT program for 5-10 years. These 
themes were social relationships, psychological well-being, employment, independence, and 
leading a meaningful life. Each of these categories were reported to be either negatively or 
positively affected by methadone treatment. While participants reported that methadone increased 
their quality of life by allowing them to handle responsibilities and function better in relationships 
with others, they also reported that being enrolled in a methadone program caused them to 
experience discrimination, which negatively affected their relationships. A positive impact on 
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quality of life within the occupation theme was related to the ability to gain employment while 
maintained on methadone, but a reported negative impact with regards to limited job 
opportunities and lack of perceived high-quality jobs was also noted. This study highlights the 
complexity of issues surrounding quality of life and OMT treatment. While participants reported 
several negative impacts that OMT has had on their lives, many of these are perhaps due to 
stigma associated with OMT (discrimination with regards to employment or relationships) rather 
than OMT itself. This study is limited by a lack of a pre-OMT comparison group, so it is 
unknown whether the participants would have reported significantly lower scores before 
treatment.  
Korthuis et al. (2011) compared self-reported health-related quality of life scores of 289 
HIV-positive individuals with opioid addiction before beginning treatment with buprenorphine to 
scores after 12 months of treatment with buprenorphine OMT at a community-based clinic. 
Utilizing the Medical Outcomes Study Short Form Health Survey (SF-12), the researchers found 
that quality of life was significantly improved (β 1.13; 95% CI 0.72, 1.54) after 12 months of 
treatment, specifically in the mental health, vitality, social functioning, and emotional functioning 
categories. Individuals with previous 30-day incarceration were found to have lower mental 
health quality of life ratings. The significance of this is unclear and may be related to the 
individuals having HIV and a history of incarceration. 
Ponizovsky et al. (2010) conducted a similar pre-post, 32-week longitudinal study of 105 
HIV-negative individuals receiving buprenorphine over the time span of 32 weeks. Several 
different scales were utilized to assess quality of life, including the Quality of Life Enjoyment and 
Satisfaction Questionnaire, General Self-Efficacy Scale, and the Multidimensional Scale of 
Perceived Social Support. After 32 weeks in treatment, there was a significant improvement 
(p<.001) in quality of life, enjoyment and satisfaction, general self-efficacy, and perceived social 
support. Importantly, these effects were achieved at 16 weeks and sustained over 32 weeks. 
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Although not specific to incarcerated individuals, these finding suggest that OMT positively 
affects quality of life. 
Although there are no studies comparing quality of life between individuals receiving 
methadone and buprenorphine, studies suggest that enrollment in either type of OMT has a 
positive impact on quality of life. Improved quality of life may provide motivation for individuals 
to avoid illicit substance use and activities, and may motivate them to make positive changes in 
their lives. While little is known about how OMT affects the quality of life of incarcerated 
individuals, the continuation of OMT upon incarceration may help individuals adjust to the prison 
setting and allow them to participate in daily activities such as work duty and classes without 
withdrawal symptoms.  Participation in educational programs while in prison has been found to 
be associated with decreased rates of recidivism upon release (Davis, Bozick, Steele, Saunders, 
Miles, 2013). Individuals may be unable to fully participate in educational programs during the 
weeks-to-months long withdrawal phase, which and may affect present and future quality of life 
as well as recidivism rates.  
Decrease in Risk of Overdose & Community-based Opioid Maintenance Treatment 
 
 Overdose is the most common cause of death among injection drug users, outnumbering 
deaths due to infectious disease (e.g. HIV, hepatitis C, tuberculosis) and non-infectious causes 
(e.g. cancers, heart disease, liver disease) (World Health Organization, 2013). Cases of non-fatal 
overdose can cause significant morbidity related to cerebral hypoxia, including permanent brain 
damage (World Health Organization 2013). The World Health Organization reports that OMT is 
responsible for a significant decrease in the risk of opioid overdose (2013).  Gronbladh, Ohlund, 
and Gunne (1990) conducted a seminal study that compared the mortality outcomes of a group of 
individuals addicted to heroin receiving methadone treatment (n=166) vs. a group of of individual 
addicted to heroin who were not receiving methadone treatment (n=115) over 8 years. The rate of 
deaths related to overdose in the group not receiving methadone treatment was found to be 
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significantly higher than in the group maintained on methadone (x2= 20.29, P<0.0001), and none 
of the individuals in the group receiving methadone died from overdose due to heroin. Causes of 
mortality in the group receiving methadone included overdose due to substances other than 
heroin, endocarditis, and liver disease. Mortality rates for individuals maintained on methadone 
were 1.4% per year, compared to 7.2% for the untreated controls and 6.9% per year for those 
involuntarily discharged from the methadone program. 
Similarly, Langendam, van Brussel, Coutinho, and van Ameijden (2001) utilized a 
prospective cohort model to study the rates of mortality from opioid overdose in drug users who 
were maintained on methadone compared to drug users who were not maintained on methadone. 
Eight hundred and twenty seven participants from the Amsterdam Cohort Study were included in 
the study. The researchers found that injection drug users who were not maintained on methadone 
were more than four times more likely to die due to overdose than injection drug users who were 
maintained, regardless of methadone dosage. More recently, a longitudinal time series analysis 
was conducted by Schwartz et al. (2013) that studied overdose deaths in Baltimore, Maryland 
between the years of 1995-2009. The researchers found that an increase in OMT availability 
throughout the city was associated with a decrease in annual deaths by opioid overdose by 37%. 
While this study found that OMT was associated with a decrease in opioid overdose, it was 
limited in that it only included overdoses from heroin and morphine, rather than overdoses caused 
by opioid prescription pain medication (oxydocone, hydrocodone, etc.).  
Methadone and buprenorphine are also associated with overdose. Utilized for pain 
control (2% of prescriptions in 2009) as well as addiction treatment, methadone was implicated in 
at least 30% of deaths involving prescription pain medication during the year 2009 (Kuehn, 
2012). However, while increased methadone prescribing for pain control has been associated with 
increases in methadone overdoses, higher rates of supervised methadone administration has been 
associated with lower rates of methadone associated overdose (Strang, Hall, Hickman, & Bird, 
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2010). Although the research is limited in this area, this suggests that the lethality associated with 
methadone and methadone overdose may be related to the clinical indications for use. For 
example, individuals receiving methadone for opioid dependence generally take methadone at 
lower dosing frequency and are maintained in a controlled environment (Substance Abuse and 
Mental Health Services Administration, 2013). Buprenorphine has been speculated to be safer 
than methadone due to the fact that it is a partial rather than full opioid agonist, which may partly 
account for its approval for administration in primary care and other less regulated settings 
(Auriacombe, Fraques, Tignol, 2001). However, buprenorphine can still cause overdose, and 
OMT clinics that prescribe it must be careful to carefully titrate doses and carefully monitor for 
signs of diversion. 
Incarcerated Populations and Opioid Maintenance Treatment 
 
The vast majority of incarcerated individuals with a history of opioid abuse do not have 
access to OMT (WHO, 2013). When individuals who are patients at a community-based OMT 
program in some states are incarcerated and their stay is estimated to be longer than 30 days, they 
are often tapered from their methadone or buprenorphine dose unless they are pregnant (Correct 
Care Solutions 2011; McKenzie et al. 2009; Fu et al., 2012). Cropsey et al. (2012) conducted a 
study in which the researchers mailed surveys regarding health care access to US prison 
administrators. Four hundred and thirty one facilities with a total of 7,843,785 inmates responded 
to the survey. It was reported that methadone was provided at 17.4% of these facilities, and 3.6% 
of inmates received treatment. Buprenorphine OMT program availability was not studied. 
Chandler, Fletcher and Volkow report that less that 1% of incarcerated individuals in the US have 
access to OMT (2009). Reasons for the discontinuation of OMT upon incarceration and the 
unavailability of OMT in prisons are not fully transparent, although they may have to do with 
concerns of diversion, logistical difficulties, and the belief that illicit substances are difficult to 
obtain in correctional facilities, as well as general stigma about opioid addiction (McKenzie et al., 
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2009). Addiction medicine is a specialty and Chandler, Fletcher, and Volkow (2009) speculate 
that few prison providers have received adequate training to provide effective substance abuse 
treatment. Lack of understanding about the neuropathology of addiction can also lead to the 
stigmatization of substance users, which can cause decreased motivation on the part of both 
prison-based health care providers and policy makers to guarantee comprehensive treatment for 
all incarcerated individuals (Chandler, Fletcher, Volkow, 2009). 
As mentioned previously, many different factors can contribute to the decision regarding 
whether to administer methadone or buprenorphine OMT to a patient. The administration of 
buprenorphine may take longer than that of methadone in a prison setting, with buprenorphine 
preparation and administration taking about 15 minutes and methadone preparation taking 1-3 
minutes in one study (Magura, 2009). It may be that health resources cannot accommodate the 
associated time burden of buprenorphine administration. Buprenorphine may also be easier to 
divert, as it is administered in a dissolving tablet or film form, while liquid methadone must be 
swallowed immediately. As diversion of medication is a serious concern in the prison setting, it 
may be another reason why prisons are hesitant to provide OMT, with either methadone or 
buprenorphine  (Magura, 2009).  
Mental Illness & Stressors in the Prison Population 
 
Incarceration can represent a major life change for many individuals and can cause stress 
related to separation from loved ones, fiscal worries (especially if the incarcerated individual had 
been financially supporting others), change in daily routine, and social difficulties with other 
inmates. For inmates who had been maintained on OMT prior to incarceration, tapering from 
OMT may be yet another cause of increased stress and come with significantly uncomfortable 
withdrawal symptoms. In addition, research suggests that prisoners report high numbers of past 
traumatic life events that can cause symptoms of post-traumatic stress disorder. Maschi, Gibson, 
Zgoba, and Morgen (2011) interviewed a random sample of 58 adult male inmates about history 
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of trauma, including abuse, witnessing violence, kidnapping, illness, and loss of a loved one. 
Forty-three percent reported being physically abused as a child, 89% reported witnessing 
violence, 61% reported seeing someone shoot another person, 29% reported experiencing a life 
threatening illness, and 88% reported the death of a loved one. Abram et al. (2007) found that 
more that 90% of incarcerated youth (n=898) interviewed reported history of a major traumatic 
event, with 11% reporting symptoms congruent with PTSD within the past year. In comparison, 
only 4-9% of non-incarcerated youth report these symptoms.  
Cauffman et al. (1998) found that 65% of incarcerated female adolescents reported PTSD 
symptoms (n=96), which the researchers state is 6 times higher than the general population. In 
addition, 41-65% of those struggling with substance abuse also have or would meet criteria for 
co-morbid mental health disorders, including anxiety disorders and PTSD (U.S Department of 
Health and Human Services, 1999). Binswanger et al. (2010) found that 44% of incarcerated 
women and 22% of incarcerated men who responded to the US Survey of Inmates at Local Jails 
reported having a mental health diagnosis other than substance abuse disorders, including 
depression, anxiety, bipolar disorder, PTSD, and psychosis. Although self reported, these findings 
suggest high levels of PTSD or general stress within the inmate population that might make 
adjustment to a substantial life change (incarceration) difficult, especially when coupled with a 
second significant stressor such as tapering from OMT. In addition, untreated mental illness in the 
prison setting can lead to issues such as inmate violence (including sexual violence) (Dumond, 
2003) and suicide attempts (Chavez, 2012). Increased stress related to untreated addiction may 
intensify these risks.   
Retention in Opioid Maintenance Treatment, Relapse, and Recidivism 
 
Gordon, Kinlock, Schwartz, and O’Grady (2008) conducted a randomized clinical trial 
that compared the effectiveness of three different types of interventions in male inmates (n=201) 
with a history of heroin addiction. Subjects were randomly allocated to receive either counseling 
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only, counseling with referral to OMT (specifically methadone) programs, and counseling with 
initiation of methadone treatment three to six months before release from prison. The counseling 
with initiation of methadone group began treatment with methadone a few weeks before their 
release dates and were then transferred to an outpatient treatment center for continuation of care 
once they were released from prison. At six months post release, 65% of counseling only 
participants, 48% of the counseling with referral participants, and 28% of the counseling with 
initiation of OMT participants tested positive for illicit opioids. The participants in the counseling 
with initiation of OMT group attended a treatment program for a significantly greater number of 
days than those in the two other groups, with the counseling only group having the lowest number 
of days. The individuals in the counseling only group also reported a significantly higher number 
of days in which they participated in criminal activity compared to the referral (p<0.0001) and 
initiation groups (p<0.002) (56.6 days vs. 35.6 and 28.5, respectively) (Gordon, Kinlock, 
Schwartz, and O’Grady 2008). These results suggest that OMT, when initiated prior to release 
from prison, may help previously incarcerated individuals avoid relapse and activities that could 
cause re-arrest. 
Kinlock, Gordon, Schwartz, Fitzgerald, and O’Grady (2009) conducted a 12-month 
follow up study post-incarceration to examine opioid relapse and recidivism. Follow up data was 
available for 97% of initial participants. Participants who had received counseling with OMT 
reported an average of 166 days in a community based clinic, those who had received counseling 
with referral reported an average of 91.3, and those who had received only counseling reported an 
average of 23.1 (Kinlock et al., 2009). This suggests that the initiation of opioid maintenance 
treatment with counseling in prison is associated with greater long-term involvement in 
community-based treatment programs after release from prison than counseling with referral or 
counseling alone.  Recidivism was not significantly related to intervention group in either study, 
but neither of the studies thoroughly analyzed the reasons for reincarceration. Kinlock et al. 
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(2009) suggest that arrests may have been related to probation violations and earlier offenses 
rather than substance abuse. 
McMillan, Lapham and Lackey (2008) conducted a retrospective chart review to study 
the recidivism history of 589 inmates at a prison in the Southwest US with an OMT program.  
The program allowed inmates who had been patients at a methadone clinic prior to incarceration 
to continue to receive methadone while incarcerated. They compared time from release to 
reincarceration of inmates who had received OMT during incarceration versus inmates who did 
not receive OMT while incarcerated. A primary reason for an inmate not receiving OMT 
involved difficulty verifying dosage history with the community-based methadone clinic. No 
significant difference in time between release from prison to recidivism and reincarceration was 
seen between the two groups. However, this study did not take into consideration whether 
inmates were able to continue OMT at a community clinic after release. It also did not examine 
any differences that may have existed between inmates who were receiving OMT in prison and 
those who were not receiving OMT besides length of time incarcerated. Length of time 
incarcerated can affect ability to receive OMT because verification of dosage with the outside 
clinic can be a lengthy process and individuals with longer sentences may be more likely to have 
their dosage verified. This study also failed to explore reasons for re-incarceration, which may 
have included issues related to probation from previous offenses and crimes that were not drug 
related.   
Larney, Toson, Burns, and Dolan (2011) found that while OMT in prison was not 
associated with reduced re-incarceration rates, continuation of treatment upon release decreased 
re-incarceration by 20%. Opioid maintenance treatment during incarceration is not itself 
associated with lower re-incarceration rates, but maintenance at community based OMT programs 
is, and OMT initiation and maintenance while in prison leads to higher rates of continued 
treatment upon release. Barriers to continuation of treatment upon release may confound the 
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benefits of prison OMT once individuals are reintegrated back into the community. Initiation 
and/or continuation of OMT in prison and the resources to smoothly transition from prison OMT 
to community OMT upon release benefits both the individuals and the greater community by 
reducing rates of re-incarceration. 
Magura et al. (2009) compared the outcomes of methadone initiation in the prison setting 
to those of buprenorphine initiation. One hundred and sixteen adult male inmates at Riker’s 
Island with heroin addiction were randomly administered methadone or buprenorphine treatment. 
The researchers found that while there was no significant difference (p<0.001) between the two 
groups in completion of the study or rates of recidivism/re-incarceration at Riker’s upon release, 
48% of the individuals who had been initiated and maintained on buprenorphine vs. 14% of the 
individuals who had been initiated and maintained on methadone continued treatment at an OMT 
community clinic upon release. The researchers believed that this vast difference might have been 
due to the relative flexibility of community based buprenorphine administration compared to 
regionalized methadone centers. This study excluded individuals who had been previously 
maintained on methadone at the time of incarceration. This is relevant because individuals who 
had been enrolled in methadone treatment before incarceration and were maintained while 
incarcerated may have continued treatment at a community clinic after release at a higher rate 
than those initiated in prison like the individuals in this study. In addition, the median dosage of 
methadone (30mg) administered in this study is considered suboptimal for most patients, while 
the median buprenorphine dose (12mg) is considered within the range of optimal for most 
patients (Magura et al., 2009). This may have contributed to the lower rates of continuation of 
treatment for those in the methadone group, as suboptimal OMT dosing is associated with less 
successful treatment (Magura et al., 2009). These results suggest that both ease of accessibility to 
treatment and proper dosages may contribute to continuation of treatment upon release, and that 
the success of OMT may be related to what type of medication is administered. 
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Health Outcomes and Risk of Overdose Following Release from Prison 
 
 Re-incarceration is not the only risk for individuals following release from prison. Health 
problems present another barrier to successful reintegration into the community, particularly 
ongoing substance abuse and mental health related issues. Binswanger et al. (2011) interviewed 
29 previously incarcerated individuals between the ages of 22-57 regarding medical issues they 
faced post-prison release. One of the themes that emerged was difficulty accessing health care, 
including mental health and addiction care. Many of the participants expressed the wish that they 
had been referred to a health care provider or community health clinic pre-release so that they 
could have easily accessed care once they left prison. For some participants, difficulty accessing 
care meant a delay in treatment for which they suffered complications such as relapse with 
substances and worsening health. The fear of relapse into substance use and potential overdose 
were reported, which the participants stated were related to inadequate access to care. These 
results suggest that access to care post-release may be improved by referrals to health care 
providers and substance abuse treatment centers prior to release from prison.  
Binswanger et al. (2012) explored the experiences that formerly incarcerated individuals 
reported having with overdose of illicit substances after release from prison. Twenty-nine 
individuals 18 or older were recruited from community health and addiction clinics and 
interviewed two months after release from prison. Three of the participants reported having 
overdosed soon after release from prison, and greater than 50% of the participants reported 
knowing someone who had experienced an overdose post-release from prison. One major theme 
reported was difficulty accessing substance abuse care post-prison release, combined with 
unavoidable exposure to drugs in their environment. The stress of reintegration back into the 
community, including finding work, shelter, and healthcare was reportedly so intense that 
returning to substance use was a commonly reported coping mechanism. The perceived sudden 
lack of structure that many individuals were faced with after living in a highly structured prison 
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environment was reported to be another stressor.  While many of the participants reported 
remaining clean from illicit substances while incarcerated, the combination of life stressors paired 
with the high levels of substance use and easy access to substances in their communities made it 
very difficult to refrain from using substances post-release from prison.  Participants also reported 
that staying “clean” while incarcerated led to a decreased tolerance for substances, which they felt 
led to an increased risk for overdose. The researchers recommended the use of opioid 
maintenance treatment both in prison and immediately following release to potentially decrease 
this risk (Binswanger et al. 2012). A potential benefit of OMT may be that it provides better 
access to care and greater structure in the every day lives of these individuals (Binswanger et al., 
2012). 
Increased risk of death related to overdose following release from prison has been clearly 
identified. Merral et al. (2009) conducted a meta-analysis that included six studies that followed 
inmates aged 18-35 with substance abuse histories for at least 12 weeks post-incarceration. One 
thousand thirty three deaths within the first 12 weeks post-prison release were analyzed. 
Individuals were at a three to eight-fold increased risk of death related to drug overdose within 
the first two weeks after prison release compared to the next 10 weeks (week two through 12). 
Seventy-six percent of deaths taking place within the first two weeks post-release were found to 
be drug-related. The authors speculated that the increase in risk of drug overdose was due to a 
possible decreased drug tolerance of inmates who were free of illicit drugs or OMT in prison. 
Increased implementation of OMT both in prison and upon immediate release could potentially 
decrease risk of post-prison release associated opioid overdose.   
Andrews and Kinner (2012) conducted a chart review utilizing the Australian National 
Coroners Information System to explore causes of death post-prison release. Three hundred and 
eighty-eight records were reviewed, 45% of which listed accidental substance overdose as cause 
of death. Eighty-two percent of the deaths were caused by an opioid, and individuals who died of 
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accidental drug overdose were more likely to have had experienced withdrawal in the six months 
preceding the incident. The use of multiple substances at one time was described in 72% of the 
deaths, with benzodiazepines and alcohol being common co-substances implicated in opioid 
overdoses.  Like many other researchers referenced above, Andrews and Kinner (2012) 
recommend the use of transitional substance abuse treatment programs as well as pre-release 
educational programs focusing on opioid overdose prevention and the dangers of polysubstance 
use to decrease the risk of post-prison release opioid overdose. 
Despite much research on the effects of prison OMT on inmates and previously 
incarcerated individuals with regards to relapse, recidivism, and health outcomes, as well as the 
rates of mental illness and distress in the prison population, little is known about the lived 
experiences of individuals who are tapered from OMT at the time of incarceration. Quantitative 
research dominates this area, and the addition of qualitative data may add some important 
perspectives concerning the ways in which previously incarcerated individuals view these 
experiences. Studies exploring the lived experiences of this population may also help guide 
focused research that may lead to more successful interventions to reduce recidivism, increase 
quality of life during incarceration and post-release, and improve opiate abuse recovery outcomes 
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Screaming Behind a Door: The Experiences of Individuals Incarcerated Without Opioid 
Maintenance Treatment 
Background & Purpose: Opioid maintenance therapy (OMT) is an effective method of treating 
opioid addiction. Of incarcerated individuals in the U.S., 50-85% have a history of substance 
abuse, and >80% of inmates with opioid addiction history do not receive treatment. The purpose 
of this study was to explore individuals’ experiences after being tapered from OMT upon 
incarceration. Methods: Interpretative phenomenological analysis (IPA) was employed using in-
depth interviewing of 10 participants. Results: Analysis identified six themes that captured the 
essence of the participants’ experiences. Implications & Conclusion: Losing OMT upon 
incarceration was described as an extremely stressful experience for many individuals, and may 
create issues for both inmates and facility staff. Further research is needed to discover ways in 
which to improve addiction treatment in prison. 
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Introduction 
Substance related offenses are responsible for at least half of federal prison sentences. 
Between 50-85% of incarcerated individuals in the U.S. have a history of substance abuse, with 
20% of those reporting intravenous (IV) drug use (Nunn, 2009).  Between 9-13% of incarcerated 
individuals in 2004 reported using heroin on a regular basis pre-incarceration (Mumola & 
Karberg, 2006), and between 12%-25% of newly arrested individuals tested positive for opioids 
upon urinalysis (National Institute of Justice, 2004). The availability of illicit substances in 
prisons has been well documented (United Nations Office on Drugs and Crime, 2010), and 
associated needle-sharing behaviors in prison settings greatly increase risk for HIV and hepatitis 
C acquisition during incarceration (United Nations Office on Drugs and Crime, 2010). Opioid 
maintenance treatment (OMT) with either methadone or buprenorphine is an effective method of 
decreasing opioid abuse and promoting increased health in community and prison settings 
(National Institute on Drug Abuse, 2012). Additionally, OMT decreases an individual’s 
involvement with the criminal justice system, risk of HIV/hepatitis C infection (Gordon, Kinlock, 
Schwartz, O’Grady, 2008), and increases quality of life in the community-dwelling population 
(Nosyk et al., 2012). While detoxification programs are also utilized for treatment of opioid 
dependence, they have been found to be less effective than OMT at reducing illicit behaviors, 
substance use, and needle sharing (Nosyk et al., 2012).  The World Health Organization (WHO, 
2013) has called for OMT to play a major role in substance abuse programs, including those in 
prison settings, and the National Institute on Drug Abuse (NIDA, 2012) includes OMT in its 
principles for addiction treatment of both the general and inmate population. 
Opioid maintenance treatment in the prison setting has been found to result in a decrease 
in opioid use as well as decreased drug injecting and needle sharing (NIDA, 2012). While 
inmates frequently report accessibility to illicit substances and means to inject drugs in prison, 
only 55% of U.S. state and federal prisons provide methadone or buprenorphine, and more than 
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half of those prisons only do so for pregnant women or to treat chronic pain rather than addiction 
(Nunn 2009). More than 80% of inmates with known addiction histories do not receive treatment 
while incarcerated (Chandler, Fletcher & Volkow, 2009). Many incarcerated individuals with a 
history of opioid abuse have been enrolled in an OMT program prior to incarceration (Fiscella, 
Moore, Engerman, Meldrum, 2004), but subsequent rates of initiation into OMT after release 
from prison are low, and the risk of overdose is elevated in the period immediately following 
reintegration back into the community (WHO, 2013).  Hendrich et al. (2011) found that six 
months following release from prison, more than 50% of individuals who were able to receive 
OMT in prison continued treatment in the community, while only five percent of individuals who 
did not receive OMT while incarcerated enrolled in a community-based OMT program upon 
release from prison. Individuals with a history of pre-incarceration heroin addiction typically 
relapsed within one month of release from prison if they were not enrolled in an OMT program 
(Gordon, Kinlock, Schwartz, O’Grady, 2008). Reasons for relapse can include anxiety and 
depression related to “stigma associated with being labeled an ex-offender, the need for housing 
and legitimate employment, stresses in reunifying with family, and multiple requirements for 
criminal justice supervision,” as well as reintegration into a community where substances are 
highly available and accessible (Chandler, Fletcher, & Volkow, 2009, p184). 
Rates of successful long term, voluntary tapers from OMT in medically supervised 
community-based treatment centers are generally considered poor. Nosyk et al.’s (2012) 
population-based, retrospective cohort study found that only 13% of community-dwelling 
individuals who attempted a medically supervised, voluntary taper from OMT were considered 
successful, meaning they avoided relapse and/or reentry into OMT. Tapers that were longer than 
12 weeks were associated with greater success than those shorter than 12 weeks. Calsyn, Malcy, 
& Saxon (2006) reported a zero percent success rate following a voluntary, medically supervised 
(minimum 120 day duration) methadone taper in a community setting, suggesting that voluntary 
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taper of methadone is difficult without the added stressors associated with incarceration. Because 
the accessibility of OMT in prison settings is poor, many individuals who are enrolled in an OMT 
program are involuntarily tapered from methadone or buprenorphine upon incarceration at a rate 
that is much faster than what is generally considered appropriate within a community-based OMT 
setting (Fiscella, Moore, Engerman, Meldrum, 2004).  Given the stress associated with 
incarceration, it is important to explore the experiences of individuals who have undergone 
involuntary discontinuation or taper while serving time in prison. The purpose of this study was 
to discover, explore, and describe individuals’ experiences of incarceration after being tapered 
from OMT upon incarceration. Implicit within the goal is to discover the essence of their 
experience during this time and learn about what the experience was like for them. 
Methodology 
Research Design 
Interpretative phenomenological analysis (IPA) (Smith, Flowers, & Larkin 2009) was 
used to explore, describe, and interpret the experiences of individuals who were involuntarily 
tapered from opioid maintenance treatment upon incarceration.   
Sampling and Recruitment 
The institutional review board approved this study prior to any study procedures. Current 
and former patients at a methadone and buprenorphine outpatient treatment center in northern 
New England who had been previously incarcerated were the population of interest in this 
qualitative study. Inclusion criteria included a history of incarceration that involved an 
involuntary taper from OMT and the ability to remember and verbally share this experience. 
Participants were 18 or older and English speaking. Exclusion criteria included inability to 
complete interviews and pregnancy, due to vulnerable population status. Purposive sampling and 
snowball sampling were utilized. Participants were recruited from the OMT clinic using flyers 
advertising the study. Counselors at the clinic were also asked to provide clients with information 
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about the study and the principal investigator’s (PI) contact information. All interested 
individuals contacted the PI directly. Sampling continued until saturation was reached at 
interview 7 with an additional 2-3 participant interviews to ensure that the multifaceted nature of 
the phenomena was well captured, and that the data included examples of both “similarity and 
difference between participants” (Smith, Flowers & Larkin, 2009, p. 51). There were a total of ten 
participants, who reported being incarcerated at 4 different facilities in New England, with the 
exception of one participant who had been incarcerated in the Southern US. A $20 gift card to a 
grocery store was provided as compensation for participant time and travel. 
Study Procedures 
  Flexible, semi-structured, in-depth interviews were conducted in private rooms at the 
treatment center that were safe, private, and convenient for the participants and the PI. Interviews 
included questions that explored the experience of being tapered from OMT, serving a prison 
sentence without OMT, and reintegration back into the community after release. The first 
question the PI asked participants was: “Tell me what happened when you were first arrested and 
incarcerated.”  Interviews lasted 45-75 minutes, and were conducted solely by the PI. Interviews 
were audio recorded and then transcribed verbatim. Throughout the study, the PI performed 
reflexive journaling in order to explore personal biases and preconceptions that may have affected 
the interviewing process (Polit & Beck, 2011). Journaling was performed after especially 
emotional interviews, when the PI was disturbed by the participants’ descriptions of mistreatment 
in the prison setting. This practice allowed the PI to remain neutral to avoid bias against facility 
staff, as well as remaining open to all individual stories of the participants. 
Data Analysis 
The interviews were transcribed verbatim and cross-checked, then de-identified. The PI 
was mindful to consider both the transcribed text and the context of the interview by analyzing 
the words chosen (including slang), the body language, and any emotional displays such as 
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laughter, weeping, etc. (Ray, 1994). The PI then identified emergent themes from the initial 
notations. The PI then considered all cases at once to discover thematic “patterns” that fully 
captured the essence of participants’ experiences (Smith, Flowers & Larkin, 2009, p. 101). To 
improve the study’s rigor, one participant was contacted for a member-check. The participant 
validated that the themes reflected her experience. 
Results 
Demographic information, utilizing pseudonyms to identify participants, is presented in 
Table 1. Six themes emerged upon analysis of the transcribed interviews: 1) “You’re not getting 
your meds” (Traumatic taper experiences), 2) “I was crawling out of my skin” (Difficult 
withdrawal), 3) “Suck it up, it’s not that bad” (Suboptimal medical care), 4) “Trapped and 
helpless” (Co-occurring mental illness), 5) “More in there than out here” (Access to substances in 
the facilities), and 6) “I just went looking on the street” (Relapse upon release). 
“You’re not getting your meds” 
 Most of the participants reported that despite what they had heard about the Department 
of Correction’s policy to taper inmates receiving OMT, they did not receive a taper. Some 
participants were told immediately upon entering the facility that their OMT would be abruptly 
discontinued. Bryce shared: “They knew I was on it when I came in and they said it didn’t matter. 
Kick rocks, pretty much.” Other participants shared that they were not immediately told whether 
they would be receiving OMT or not. Mason said: “They didn’t give me anything…and nobody 
told me nothing. And that’s kind of intense, kind of sucks.” One participant, Sierra, stated that she 
had to make a scene in order to find out if she was going to receive OMT. She angrily recalled 
this experience: “it took like 3 or 4 nights until I started flipping out…screaming behind a door, 
like ‘what the fuck is wrong with you people, get someone who does know what’s going on, you 
fucking moron’….you have to get them mad at you, until finally, they’re like ‘she won’t shut up 
in there’…finally hours later, one the nurses comes down…she’s saying ‘you’re not going to get 
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your meds.’” Participants expressed confusion, anger, and frustration about these policies and 
wondered why the process couldn’t have been more clear. 
All of the participants but one were vehement in their belief that the experience of either 
abruptly losing or being tapered from OMT was an unquestionably negative experience. Zev 
shared that the taper experience was not only severely uncomfortable, it also negatively impacted 
his recovery upon release: “It makes you angry. You kind of stay angry…because you just don’t 
care anymore. You’re just like, ‘fuck it, I don’t care. I just want to be high.’” Lila, a participant 
who did receive a taper from OMT, reported mixed feelings about this experience:  
You know, I’m caught here. Part of me says maybe it was a good thing because it 
kind of made me realize, yeah, I can do this without it. So I mean…maybe it was 
a good thing. I don’t know. Part of me says it’s a good thing and part of me says 
deal with one thing at a time. 
 
Although no other participants expressed the belief that the taper or discontinuation experience 
may have been positive, many others echoed the sentiment that dealing with incarceration and 
“detox” at the same time was overwhelming. Sierra wondered how the experience fit in with the 
goal of rehabilitation, which she believed was the purpose of prison: “All those girls are just 
going through emotional hell and I can’t see how that could in any way—that experience could 
help anyone. It’d have to cause more trouble. You know?” In summary, all participants reported 
that losing OMT, either with a taper or in the case of abrupt discontinuation, was a stressful 
experience. In addition, some reported that the experience negatively impacted their recovery 
process after release. 
“I was crawling out of my skin” 
 All participants reported an extremely challenging withdrawal, regardless of whether they 
had received a taper or abruptly discontinued OMT. Some participants focused on physical 
withdrawal symptoms. Jeremy shuddered while recalling his experience: “Every single day was 
just dreadful…like I’d get so hot that I’d sweat…I’d shiver and when I was throwing up I wasn’t 
throwing up anything. Just foam. Just big, big things of foam and it was nasty.” However, most 
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stated that withdrawal while incarcerated was both physically and emotionally taxing. For Bryce, 
memories of the emotional turmoil were more vivid:   
I felt like it screwed my head up afterwards for awhile. I didn’t feel clear for a 
long time…I felt like I was nursing my mind and my body back to health 
slowly…It’s a horrible experience. Its really—emotionally its even harder. I can 
take the sickness, but you know you’re in jail and you’ve lost everything again 
and you’re—I feel like I’m always like—my body is an open wound 
emotionally…Then I just starting thinking about my kids and its just…it’s a 
dreary place to be. 
 
A few participants reported that even once the acute withdrawal symptoms faded, they 
had difficulty engaging and integrating themselves into day-to-day prison life. Donna described 
feeling detached: “I just didn’t feel right. Like I was there but I wasn’t kind of. I was very 
spacey…I was seeing and doing everything but I really wasn’t in my body doing it…I was just 
extremely out of it for probably five months.” The withdrawal experience in prison was 
physically and emotionally challenging for all of the participants, and some reported that after 
effects associated with withdrawal took months to wear off. 
“Suck it up, it’s not that bad” 
 Despite how ill the participants were during their withdrawal periods, none reported 
receiving comprehensive medical care. While some were given “cocktails” for symptom 
management (usually including Pepto-Bismol, clonidine, and an anti-histamine) or “vital checks” 
(facility staff checks vital signs such as blood pressure and pulse in order to monitor withdrawal), 
others reported feeling ignored by the medical staff. Mason received no medical attention: “The 
nurses knew about when I was being tapered down, they didn’t come and check. Nobody came to 
check nothing.” Donna stated: “They just sat there and said ‘suck it up, its not that bad.’ The most 
they would do was give me juice at times because they thought I was going to pass out and they 
wanted to get some sugar in my system.” Bryce discovered that pretending to be an alcoholic 
helped him receive treatment for withdrawal: “The medical staff is horrible…their opinion is, you 
can’t die from opiate withdrawal, so suffer. All of us learned to say that we were drinking 
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heavily—they give you Valium for drinking…I don’t drink but I told them that because it was the 
only way.” 
A few participants stated that they had been placed in a “medical unit” to withdraw, 
which they described as feeling more like solitary confinement or “the hole.” Jeremy stated:  
I told them I was going to crash real hard and they said, ‘Well, then, what we 
need to do is lock you into an empty room’ and gave me a bucket...They didn’t 
do anything for me, wouldn’t give me any medication [to help with withdrawal 
symptoms]. 
 
These participants reported feeling so lonely and frightened in the medical units that they 
pretended to be finished withdrawing so that they could join the general prison population. Angel 
said:   
I was in medical for 5 days and then…I pretty much lied and said I wasn’t 
detoxing anymore…I just didn’t want to be in there. I didn’t want to be in the 
hole…I just wanted to be in [general] population. 
 
Some participants reported feeling discriminated against by medical staff for having an 
addiction history. Bonnie reported that her symptoms weren’t taken seriously because they were 
related to opioid withdrawal:  
They didn’t seem to believe me when I said it was a medical issue. They kind of 
scoffed at that. And they were like ‘Oh, you’ll be alright.’ And I was like ‘Oh, 
yeah, right.’ And boy, I wasn’t alright. And—yeah, it was a bad experience. Just 
thinking about it gives me the creeps. 
 
Bryce echoed this sentiment: “The medical staff look at you like you’re a piece of shit…they’re 
very judgmental, which I don’t think you should be working in a correctional facility.” Many 
participants stated that they did not feel like medical staff were interested in helping them or 
improving their health status. Sierra wondered why any nurse would choose to work in the prison 
system: “I think that maybe I wouldn’t want to go to school to be a nurse and work there, because 
you can’t help anybody. So you’d either have to be mean or not care and need money really bad.” 
A lack of perceived comprehensive, compassionate health care in prison was stressed by all of the 
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participants, and some reported feeling as though the health care providers did not care whether 
they remained healthy. 
“Trapped and helpless” 
 Many of the participants shared that they struggled with mental illness as well as 
addiction issues. Two participants stated that their psychotropic medication was withheld, despite 
having a prescribing practitioner in the community. Zev shared that he had been prescribed 
multiple medications for depression and anxiety, but it took weeks for his medications to be 
confirmed with his prescribing physician. Once his medications were confirmed, the correctional 
facility’s physician decided not to prescribe some of the medications he had been getting before 
incarceration. He felt that this lapse was detrimental to his mental health:  
They’re like ‘Eh, no big deal.’ Like…times when I’ve come down off my regular 
antidepressants and stuff like…it’s so bad, it can make me want to kill myself or 
super angry and like it’s just terrible that they can do that…the doctor without 
talking to you can just decide that he knows better than the doctor you see that 
knows you…without actually interviewing or talking to you really. They can just 
be like ‘Yeah, I don’t think you need that.’ 
  
Donna had a similar experience: “I have bipolar…and they wouldn’t give me any of my 
medications. I was on Seroquel. They wouldn’t give me any of that. I was on Klonopin…they 
wouldn’t give me anything. None of my prescriptions.” 
 Other participants reported that appointments with mental health counselors and support 
meetings were hard to come by. Donna was the only participant who reported having access to a 
case manager to talk to while incarcerated, but she only met with her once because she did not 
feel comfortable talking with her. She stated that the case manager ignored her concerns and did 
not take her seriously when she tried to report that guards were sexually assaulting inmates:  
I told someone…a person that you were allowed to talk to if you were on drugs 
and you’d get to see them once a week for half an hour and you’d tell them how 
you’re doing and stuff like that…she was just like ‘that doesn’t happen,’ just kind 
of like brushed it off her shoulder like it was no big deal. 
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Max stated that despite the fact that the majority of the fellow inmates he knew had opioid 
problems, there were few substance abuse resources: “There were AA meetings…but never any 
real Narcotics Anonymous meetings…95 percent of the people were in there for like theft or 
stealing something, selling stolen property, all just to pay for their drugs.” Despite the fact that 
many of the participants reported a history of mental illness or episodes of depression and anxiety 
triggered by incarceration, none were able to access mental health care while incarcerated. 
“More in there than out here” 
 All of the participants stated that substances and drug paraphernalia were accessible in 
prison, although there were varying reports about where the drugs came from. Donna reported 
that male guards smuggled substances into the facilities in order to bribe inmates that were known 
to have addiction issues to engage in sexual favors:  
They would want me to do a sexual favor and then they would give me 
whatever…if you’re coming off stuff and it looks like you want something, 
they’re going to ask you ‘What do you want?’ and they would bring us anything 
that we wanted…whether it was drugs or alcohol or needles to do the drugs with 
or weed or cigarettes or tobacco whatever. 
 
The trades were sometimes forced: “There was one girl in there that was very young…all the 
guards wanted her. Two guys at once wanted to take her and they did—for drugs. And even if 
you said no, sometimes they still did it.” The four other female participants confirmed that they 
had either witnessed or participated in similar transactions.  
Some male participants reported that they had received substances from guards, although 
they stated that the guards were interested in money rather than sex. Jeremy told a story about a 
guard who smuggled tobacco into prison for him to sell:  
There was this female guard that worked there…I said ‘What are you making for 
money here?’ And she said ‘$15 an hour.’ And I said ‘How would you like to 
make $500 in an hour?’ And she said ‘Let’s hear it.’  
 
Participants stated that substances were also smuggled in by other inmates, who would then sell 
or use them. Selling substances in prison was identified as a lucrative business, as many desperate 
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inmates were willing to pay high prices. According to Mason, “[An 8mg pill of buprenorphine] is 
at least $100, probably $150…it’s like $20 for one little line…its highway robbery. But because 
we’re addicts, we’re going to pay whatever.” Many participants reported that individuals worried 
about withdrawal smuggled medication into the facilities when they were incarcerated to treat 
their symptoms:  
…that’s what most people know now…they know they’re not going to get their 
medicine so [they smuggle it in]. You’d be crazy not to take care of yourself…If 
I was ever in trouble again, I would bring [drugs] in because I would never go 
through that again. It was awful. 
 
So many individuals were reportedly smuggling in substances that it might have been easier for 
some individuals to find drugs in prison than in the community: “Sometimes there was more in 
there [prison] than out here. It’s like when everybody knows they’re going to jail, they do 
whatever they have to do to bring [drugs] in.” Mason reported that substances were so accessible 
that some inmates became addicted while serving time: “People would get the habit, there was so 
much down there. They were catching habits in jail. Some guys…they’d never even been on the 
street to buy [drugs] until they got in there.” 
The easy accessibility of substances despite the unavailability of methadone or 
buprenorphine for regulated treatment in prison led many of the participants to wonder about the 
futility of the tapers:  
It’s a really big deal there because everyone wants their medicine. It’s really 
stupid because most people—most of the entire [prison] population is going to be 
back on the medicine when they get out. Most of them aren’t even in there for 
more than a year…I mean, if you’re going to give it to them and then take it 
away—what a mess.  
 
Bryce reflected on his belief that the refusal by the facilities to provide addiction treatment is 
what led to the frequent drug use that they were trying to avoid:   
Its silly…they fight so hard to keep [drugs] out of jails…they should just give 
[OMT] to anybody who wants it…I just think it’s comical that they fight so hard 
to keep it out when they would solve all their problems if they just prescribed it 
as a tool for treatment in jail. 
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Every participant reported either using substances while in prison or being aware that substances 
were easy to access. Many participants shared that guards smuggled substances into prison, and 
all of the female participants had either witnessed or participated in a drug trade that involved 
sex. 
“I just went looking on the street” 
 Every participant either reported using smuggled substances while in prison or relapsing 
soon after release from prison. Some were able to re-enter treatment programs after release, but 
even those participants reported a period of time of waiting to re-start treatment in which they 
were using substances on the street.  Sierra reported using drugs right after release: “I got 
out…and just went looking on the street.” For Donna, memories of her experiences in prison 
drove her to use drugs upon release:    
It was really bad. I mean, I thought I was going to die, I was doing so many drugs 
[after release]. I really thought I was going to die…[the incarceration experience] 
was traumatic and I was having nightmares and I couldn’t get them to go away so 
I was trying to use [drugs] to make them go away.  
 
Although no participants reported overdosing after release, a few stated that they knew people 
who had. Zev stated: “ I’ve heard that a lot of people OD [immediately after release]…[some 
people] would just want to kill themselves. Because even though you’re out, its still shit.” Angel 
reported a more severe addiction once she was released than before incarceration: “Hell. I got 
extremely, extremely heavy into dope. I was doing maybe 20 bags a day.” Illicit opioid use upon 
release was reported by all of the participants, and some stated that their use after incarceration 
was heavier than their use before. Many participants shared stories of friends or acquaintances 
who had overdosed when they were released from prison.  
Discussion 
 The purpose of this study was to explore and describe the experiences of individuals who 
had their opioid maintenance treatment tapered or discontinued abruptly upon incarceration. The 
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six themes uncovered in the analysis of the interviews reflect the profound isolation from the 
outside world during incarceration that participants described, especially with regards to the 
reported disconnect between what is considered appropriate mental health/substance abuse 
treatment and what is received in prison. The participants shared examples of how the practice of 
taper or abrupt discontinuation of OMT in the prison setting may have been quite futile and in 
fact created a host of issues for both inmates and Department of Corrections staff. 
 Participants experienced feelings of isolation when they were incarcerated, both isolation 
from the outside world by virtue of being prisoners and from general prison life because of their 
addiction. Implicit in many of the participants’ stories was the feeling of not being listened to or 
having basic needs met. Participants credited this to both their status as prisoners and as addicts. 
The participants’ accounts of their experiences also point to a disconnect between what is 
provided in the prison setting and what is regarded as acceptable substance abuse treatment in the 
addiction treatment field. These findings echo Cropsey et al.’s (2012) research, which found that 
only 17.4% of 431 facilities offered methadone maintenance treatment. This leaves most facilities 
without basic substance abuse treatment. While Cropsey et al. found that 72.3% of facilities 
reported offering “co-occurring mental and substance use disorders counseling,” none of the 
participants in this study reported opportunities for counseling that were offered consistently and 
felt safe. A combination of OMT and counseling is generally accepted as standard practice for 
treatment of opioid addiction by experts in the substance abuse treatment field, and is 
recommended by the National Institute on Drug Abuse (2014). 
The participants’ reports of relapse upon release are consistent with the findings of 
Binswanger et al. (2012) and highlight one of the dangers that face inmates once they leave 
prison. Taken together with the accessibility of substances in prison, the purpose of discontinuing 
OMT is questionable. If imprisonment is meant to provide rehabilitation or at least discourage 
individuals from engaging in the behavior that led to their arrest, a policy that results in the 
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continued use of illicit substances and negatively effects recovery seems futile. The interruptions 
in OMT treatment that can occur when patients are incarcerated may lead to increased utilization 
of resources related to re-admission and re-induction at OMT clinics in the community upon 
release.  
These findings could inform changes in practice and policy, as well as further research. 
Firstly, the loss of OMT upon incarceration, with either a taper or in the case of abrupt 
discontinuation is a stressful experience for many individuals, which may have detrimental 
effects on their physical and mental health. In addition, inmates may not feel as though their 
health needs are adequately addressed by prison medical staff.  The general distrust of the 
medical staff described by the participants may lead to a failure to report serious medical 
symptoms out of the belief that medical staff will do nothing to help. The unavailability of OMT 
may lead to increased smuggling of substances into the prison setting, risky use patterns, and 
potential corruption of staff, as is also suggested by Schwitters (2014). The findings of the present 
study can be added to the growing body of knowledge that suggests that improvements in the 
treatment of substance abuse disorders in the prison setting may lead to improved rehabilitation 
while in prison, outcomes upon release, and more appropriate use of health care resources. 
Further research in this area, including interviews of prison medical staff, may help illuminate 
ways in which to improve substance abuse treatment in facilities.  
This study had a few limitations. The sample was racially homogenous, with all ten 
participants identifying as white. In addition, because the study’s inclusion criteria required that 
participants share their experiences in English, the results may not reflect the experiences of non-
English speaking populations.  All but one participant were enrolled in an OMT program at the 
time of the study, and the experiences of individuals who do not re-enter treatment after release 
may differ.  
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Conclusion 
 This study adds valuable qualitative data to the body of knowledge concerning substance 
abuse treatment in prison settings. The participants shared that experiences that reflect less than 
optimal physical and mental health care, especially with regards to their substance abuse and 
mental health issues. These stories should prompt further study to explore the current state of 
substance abuse treatment for incarcerated populations. Further research in this area may help 
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